Active substance
Results for the substance deucravacitinib
1 result
About this active substance
Deucravacitinib is a selective tyrosine kinase 2 (TYK2) inhibitor used for the treatment of moderate to severe plaque psoriasis. It works by inhibiting the interleukin signaling pathway, reducing inflammation and skin cell proliferation.
The medication is taken orally, usually once daily, with the dose adjusted based on the patient's response. Common side effects include upper respiratory infections, headaches, nausea, and elevated liver enzyme levels.
Deucravacitinib is contraindicated in patients with active severe infections or hypersensitivity to the active substance. Its use also requires careful monitoring to prevent infectious or hepatic complications.
This medication is an innovative option for patients with severe psoriasis, helping to reduce symptoms and improve their quality of life.
The medication is taken orally, usually once daily, with the dose adjusted based on the patient's response. Common side effects include upper respiratory infections, headaches, nausea, and elevated liver enzyme levels.
Deucravacitinib is contraindicated in patients with active severe infections or hypersensitivity to the active substance. Its use also requires careful monitoring to prevent infectious or hepatic complications.
This medication is an innovative option for patients with severe psoriasis, helping to reduce symptoms and improve their quality of life.